Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
palivizumab biosimilar MB05
- Development stage
- Phase 1
- Lead developer
- mAbxience
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
MB05 is a **biosimilar of palivizumab**, a humanized monoclonal antibody developed for the **prevention of respiratory syncytial virus (RSV) infections**, especially in high-risk infants. Like the original, it targets the RSV F protein and inhibits viral fusion with host cells. MB05 is being developed by mAbxience and the University Medical Center Utrecht and is administered by intramuscular injection. Its clinical development focuses on establishing bioequivalence to Synagis (palivizumab)[3][5].
- Other names
- palivizumab biosimilar MB05MB05MB-05MB 05
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on palivizumab biosimilar MB05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on palivizumab biosimilar MB05.